Biosimilar drugs step up complexity


The first ever generic monoclonal antibody therapies have been recommended for approval in Europe. The two biosimilar versions of infliximab (Johnson & Johnson’s Remicade) have passed assessment by the European Medicines Agency’s committee for medicinal products for human use, but will need to be fully approved by the European commission before they can be marketed.

Monoclonal antibodies are significantly larger and more complex than previously approved biosimilars, which include growth hormones and erythropoietin. Proving that they are functionally similar to the original drug is therefore complex. Both manufacturers, Celltrion and Hospira, had to complete human trials to prove that their generic infliximab products were as safe and effective as Remicade in treating autoimmune diseases.

Johnson & Johnson still has patent protection for Remicade in the majority of European countries. This means that the biosimilars, if finally approved, will either have to launch first in peripheral markets, or try to overturn the patent in court.


Related Content

Cast from the same mould?

31 May 2011 Premium contentFeature

news image

Development of generic biological drugs is gathering momentum. But as Rajendrani Mukhopadhyay finds out, the welcome they are...

US poised to approve its first ‘biosimilar’ drug

9 January 2015 Business

news image

FDA panel recommends Sandoz’s copy of Amgen’s Neupogen

Most Read

Self-cleaning sensors see the light

23 January 2015 Research

news image

Overcoming electrode fouling in biomedical and environmental detectors

Flowing rivers of mercury

7 January 2015 Feature

news image

Philip Ball investigates claims that the burial chamber of China’s first emperor contains rivers of shimmering mercury

Most Commented

Undeniable: evolution and the science of creation

7 January 2015 Review

news image

Evolutionary arguments

The big experiment

23 January 2015 Critical Point

news image

Plans to stop assessing school pupils’ practical work are the wrong solution to a genuine problem, says Mark Peplow